Computational evidence
| Protein change | ||
| Missense predictors do not apply to this variant type; conservation carries the signal. | ||
| Splicing | ||
| SpliceAI | — | not assessed · no allele here is in the release |
|---|---|---|
| Constraint at this position | ||
| Conservation | phyloP 0.58 | GERP -3.9 |
| Overall | ||
| CADD | 3.054 | PHRED · no single calibrated threshold — expert panels disagree |
Population frequency
| Ancestry group | Frequency | 1 in |
|---|---|---|
| South Asiangrpmax | 49.9% | 2 |
| Finnishnot grpmax-eligible | 39.7% | 3 |
| Middle Eastern | 37% | 3 |
| Ashkenazi Jewishnot grpmax-eligible | 36.5% | 3 |
| East Asian | 35.5% | 3 |
| Remaining individualsnot grpmax-eligible | 33.8% | 3 |
| European (non-Finnish) | 32.6% | 3 |
| Admixed American | 32.2% | 3 |
| Amishnot grpmax-eligible | 28.5% | 4 |
| African / African-American | 23.2% | 4 |
Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.
Variant & gene context
- Gene
- BRCA1
- Protein
- p.Ser694=
- Coding
- c.2082C>T
- MANE Select
- NM_007294
- dbSNP
- rs1799949
- Type
- single nucleotide variant
- Location
- chr17:43093449 (GRCh38)
- Gene constraint
- LOEUF 0.885 · pLI <0.01 · ClinGen HI 3/3 (gnomAD)
- Structure
- AlphaFold pLDDT 41.99 · 33 PDB
- Residue 694
- a modified residue (phosphoserine); the 'disordered' region
Disease context
breast-ovarian cancer, familial, susceptibility to, 1 — disease report on Sugi Atlas → Associated genes, phenotypes, clinical trials & treatmentsAlso linked: hereditary breast ovarian cancer syndromepancreatic cancer, susceptibility to, 4hereditary neoplastic syndromehereditary breast carcinomaFanconi anemia, complementation group S
For Hereditary breast and/or ovarian cancer syndrome (Orphanet):
- Inheritance
- Autosomal dominant
- Onset
- Adult, Elderly
Similar variants
- BRCA1 p.Ser694Asn Conflicting classifications of pathogenicity ★ ⚠ same residue
- BRCA1 p.Ser694Gly Conflicting classifications of pathogenicity ★ ⚠ same residue
- BRCA1 p.Ser694Thr Conflicting classifications of pathogenicity ★ ⚠ same residue
- BRCA1 p.Ser694Arg Likely benign ★ same residue
- BRCA1 p.Ser694fs Pathogenic ★★★ same residue
- BRCA1 p.Ser694Ter Pathogenic ★★★ same residue
- BRCA1 c.134+3A>T Likely pathogenic ★★★ same condition
- BRCA1 c.135-1G>T Pathogenic ★★★ same condition
Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →
Cite Sugi Variant
Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/brca1-p-ser694 (accessed [today's date]).
Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown